MGF (Mechano Growth Factor)

Synthetic MGF-E (the C-terminal E-domain peptide of the IGF-1Ec splice variant) applied to cultured human muscle progenitor (satellite) cells increased their proliferative lifespan and delayed replicative senescence, and enhanced their fusion potential into myotubes. The effect was significant in cells derived from neonatal and young-adult donors but was absent in cells from old-adult muscle, indicating an age-dependent responsiveness. The data support a model in which the MGF E-peptide acts upstream of differentiation to expand the proliferating myogenic pool.

In lab dishes, researchers added the MGF E-peptide to human muscle stem cells and found it helped those cells divide more times before wearing out and made them better at fusing together to form muscle fibers. This worked for cells from young donors but not from older donors, hinting that MGF may lose effectiveness with age. This was a cell-culture study, not a study in living people.

This independent laboratory tested the synthetic MGF E-domain peptide at concentrations up to 500 ng/ml on C2C12 myoblasts and primary human skeletal muscle myoblasts and found no increase in proliferation, no change in differentiation, and no detectable receptor-mediated signaling. The authors were unable to reproduce previously reported proliferative effects and questioned whether the isolated E-peptide has a meaningful physiological function distinct from the mature IGF-1 region. The work serves as a key negative-control counterpoint to earlier positive reports, most of which originated from a single research group.

A separate team of scientists ran careful experiments to check whether the MGF peptide actually makes muscle cells grow, and they found no effect at all, even at high doses. Their inability to reproduce the earlier positive results is an important caution: the case for MGF is not settled and much of the supporting evidence comes from one group. This was also a cell-based study, not a human trial.

The MGF E-domain peptide was taken up rapidly by cardiac cells via an IGF-1-receptor-independent mechanism and localized to the nucleus. Under stress it blocked apoptosis by preserving mitochondrial function and preventing caspase-3 activation, and when administered to mice undergoing myocardial infarction it improved contractility, reduced pathologic hypertrophy, and decreased apoptotic cell death in surviving myocardium. The authors proposed the peptide as a way to modulate local IGF-1 actions to protect the heart after infarction.

In mice having heart attacks, giving the MGF E-peptide helped heart cells resist dying and kept the heart pumping better, apparently by protecting the cells' energy machinery. Interestingly, it seemed to enter cells and act without using the usual IGF-1 receptor. These are results in mice and isolated cells, so they show promise but do not yet apply to human patients.